An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-<i>Mycobacterium abscessus</i> activity.

ABSTRACT: Antibiotic therapy for Mycobacterium abscessus infections is challenging due to resistance of the organism to many clinically available antimicrobials. Here, the efficacy of NITD-916, an enoyl-ACP reductase inhibitor, in preventing M. abscessus growth in vitro and in vivo is demonstrated. The minimal inhibitory concentrations (MICs) of NITD-916 for 12 non-tuberculosis mycobacteria (NTM) reference strains and a collection of 194 clinical M. abscessus isolates were determined using the broth microdilution method. Compatibility of NITD-916 with 10 clinically important antibiotics was ascertained by checkerboard assay. The activity of NITD-916 against M. abscessus growing in cultured macrophages was also evaluated. Finally, the potency of NITD-916 i

SUBMITTER: Jia Y 

PROVIDER: S-EPMC12217450 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature